AU2003302893A1 - METHODS FOR SUSTAINING eNOS ACTIVITY - Google Patents

METHODS FOR SUSTAINING eNOS ACTIVITY

Info

Publication number
AU2003302893A1
AU2003302893A1 AU2003302893A AU2003302893A AU2003302893A1 AU 2003302893 A1 AU2003302893 A1 AU 2003302893A1 AU 2003302893 A AU2003302893 A AU 2003302893A AU 2003302893 A AU2003302893 A AU 2003302893A AU 2003302893 A1 AU2003302893 A1 AU 2003302893A1
Authority
AU
Australia
Prior art keywords
sustaining
methods
enos activity
enos
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302893A
Inventor
Jane Freedman
Sibaji Sarkar
Sonia Varghese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of AU2003302893A1 publication Critical patent/AU2003302893A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G01N2333/90248—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13
    • G01N2333/90251—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13 with a definite EC number (1.14.13.-)
    • G01N2333/90254—Nitric-oxide synthase (NOS; 1.14.13.39)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003302893A 2002-12-06 2003-12-04 METHODS FOR SUSTAINING eNOS ACTIVITY Abandoned AU2003302893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43163302P 2002-12-06 2002-12-06
US60/431,633 2002-12-06
PCT/US2003/038374 WO2004052364A1 (en) 2002-12-06 2003-12-04 METHODS FOR SUSTAINING eNOS ACTIVITY

Publications (1)

Publication Number Publication Date
AU2003302893A1 true AU2003302893A1 (en) 2004-06-30

Family

ID=32507769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302893A Abandoned AU2003302893A1 (en) 2002-12-06 2003-12-04 METHODS FOR SUSTAINING eNOS ACTIVITY

Country Status (3)

Country Link
US (2) US20060127385A1 (en)
AU (1) AU2003302893A1 (en)
WO (1) WO2004052364A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004257167B2 (en) * 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302893A1 (en) * 2002-12-06 2004-06-30 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
WO2005049832A2 (en) * 2003-11-14 2005-06-02 Yale University FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
JP2011510933A (en) * 2008-01-31 2011-04-07 モナシュ ユニバーシティ Methods for treating thromboembolic disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
JPH0747582B2 (en) 1989-12-11 1995-05-24 杏林製薬株式会社 Quinazoline-3-alkanoic acid derivative and its salt and process for producing the same
JP3497164B2 (en) 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション Bicyclic fibrinogen antagonist
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5389631A (en) 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5559127A (en) 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US20020128434A1 (en) * 1993-12-08 2002-09-12 Zimmerman Mary P. Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
WO1998011066A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US6191103B1 (en) * 1997-12-05 2001-02-20 The Regents Of The University Of California Methods for enhancing thrombolysis in a mammal
ATE401312T1 (en) * 1997-12-15 2008-08-15 Astellas Pharma Inc PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES
US7078382B1 (en) * 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6448245B1 (en) * 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
AU2003302893A1 (en) * 2002-12-06 2004-06-30 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004257167B2 (en) * 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression

Also Published As

Publication number Publication date
US8586292B2 (en) 2013-11-19
WO2004052364A1 (en) 2004-06-24
US20110124512A1 (en) 2011-05-26
US20060127385A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
AU5696602A (en) Activity management method
AU2003259152A1 (en) Cell therapy for regeneration
AU2003265509A1 (en) Neurostimulator
PT1583763E (en) Benzoazolylpiperazine derivatives having vr1-antagonist activity
AU2003284254A1 (en) High activity small crystal zsm-12
AU2003269751A1 (en) Immobilization method
AU2003282268A1 (en) Activity monitoring
AU2003280129A1 (en) Activity monitoring
AUPS160602A0 (en) Therapeutic method
AU2003278355A1 (en) Process
AU2003222120A1 (en) Oxon process
AU2003258070A1 (en) Electrodionization method
AU2003235870A1 (en) Additional support structure for robot
AU2003302893A1 (en) METHODS FOR SUSTAINING eNOS ACTIVITY
AU2003208693A1 (en) Manipulator
AU2003261366A1 (en) Methods for regulating brca1-brca2-containing complex activity
AU2003202286A1 (en) Multiple award optimization
AU2003253813A1 (en) Method for colpoplasty
GB0306999D0 (en) Tots tower doorway activity
AU2003217037A1 (en) Stem cell therapy
AU2003293382A1 (en) Methods for identifying the activity of gene products
AU2003235908A1 (en) Compounds against helicobacter activity
AU2003264722A1 (en) Methods
AU2003278535A1 (en) Histoscreen method
AUPS338802A0 (en) Simulator

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase